expect beat much better expect notabl strength
broad-bas revenu guidanc light expect larg
attribut fx conservat believ risk/reward becom
interest confid build outlook continu strong growth key
product line euroimmun vanadi other p-t
revenu beat consensu forecast rel
consensu beat larg driven strong da growth da revenu
consensu diagnost revenu larg line organ revenu
growth exclud euroimmun impress highest growth rate
recent histori though acknowledg y/i comparison favor importantli
euroimmun growth mid-teen first half least good
gross margin y/i expect spite
appear greater typic mix instrument revenu oper margin
expand y/i beat consensu forecast key
driver beat rel forecast strong gross margin perform
ep increas robust y/i beat expect rel
forecast beat entir driven revenu margin upsid
report revenu guidanc updat fx increment
headwind partial off-set strong perform full year
organ revenu growth guidanc increas full year ep
expect approxim increas bridg fx tax
core revenu guid consensu head print
 delta larg due fx conservat ep guid
line prior expect
past year increas invest made sever portfolio
chang divestitur acquisit launch number new product
action appear bear fruit compani increas core guidanc second
consecut quarter report highest organ revenu growth rate recent histori
comparison favor still solid quarter believ risk/
reward get interest confid build outlook msd core revenu
growth growth euroimmun particularli share still trade
discount peer price-to-earnings basi new p-t base ep
multipl repres slight discount peer
pleas see page report import disclosur
past year increas invest made sever portfolio chang
divestitur acquisit launch number new product action
appear bear fruit believ risk/reward get interest confid
build outlook msd core revenu growth growth euroimmun
p-t base ep
ep trend slightli ahead expect
revenu growth acceler
hsd
revenu growth limit
beyond
deploy strategi ep
deploy strategi ep
margin improv come short
balanc invest growth area
ou growth demonstr potenti
provid divers array product servic address
diagnost research environment industri laboratori servic market report
two busi segment discoveri analyt solut diagnost
compani report thomson eikon cowen compani
cowen vs consensu mm except organ base ei organ organ fxgross oper margin y/i revenu metric mm except analyt currenc growth growth currenc growth organ growth statement mm except organ includ per count expens percentag revenu forecast sg expens percentag revenu forecast oper margin expand y/i beat consensu forecast key driver beat rel forecast strong gross margin perform ep increas robust y/i beat expect rel forecast beat entir driven revenu margin upsid streetaccount consensu organ da revenu beat consensu key driver overal revenu beat manag note broad-bas strength life scienc appli market sale biopharma note particularli strong appli market growth also solid led industri environment asian food test end market streetaccount consensu organ diagnost revenu line consensu revenu growth exceed expect solid quarter even consid favor y/i comparison notabl strength broad base euroimmun growth first half revenu beat consensu forecast rel consensu beat larg driven strong da growth da revenu consensu diagnost revenu larg line organ revenu growth exclud euroimmun impress highest growth rate recent histori though acknowledg y/i comparison favor importantli euroimmun growth mid-teen first half least good expect gross margin y/i expect spite appear greater mix instrument revenu cowen
compani report cowen compani
mm except yr core negligbl fx account organ fx ei growth currenc organ exchang analyt organ account growth note food businessconst currenc note onesourc businessorgan organ total exchang core dx excl ei ei contribut account dx organ growth tradit organ growth currenc organ core growth exclud ei ei add core growth total ei grow y/i exchang cowen
compani report thomson eikon cowen compani
mm except yr cagrcommentsnet core negligbl fx organ fx ei gm expand y/i expect increas revenu gener sg expect increas revenu oper oper margin y/i reiter non-oper interest net interest chang earn tax rate per share bridg fx tax core consensu except gross op cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
downsid risk includ limit macroeconom deterior
current level inabl execut integr eros market share price
due competit inabl deliv incremental/decrement margin target
value-destruct upsid risk includ limit better expect
revenue/ep disciplin buyer seller improv
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
cowen compani llc and/or affili expect receiv intend seek compens invest bank servic next month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen credit research trade due natur fix incom market issuer debt secur issuer discuss cowen credit research trade
research report assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon
analysi reflect analyst opinion date report expect continu analysi addit report relat issuer debt secur
time time cowen credit research trade research analyst provid invest recommend secur subject report
recommend intend time date public within paramet specifi individu report cowen credit research trade
invest recommend made strictli case-by-cas basi recommend provid part overarch rate system set consist
appli benchmark view express report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc august et dissemin august et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
